参考文献/References:
[1].Collaborators GBDCOD. Global,regional,and national age-sex specific mortality for 264 causes of death, 1980-2016:a systematic analysis for the Global Burden of Disease Study 2016[J]. Lancet,2017,390(10100): 1151-1210.
[2].Silverman MG,Ference BA,Im K,et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions[J]. JAMA,2016,316(12):12891297.
[3].Catapano AL,Graham I,de Backer G,et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias[J]. Rev Esp Cardiol (Engl Ed),2017,70(2):115.
[4].Grundy SM, Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol:executive summary:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines[J]. J Am Coll Cardiol,2019,73(24):3168-3209.
[5].Mammen AL. Statin-associated autoimmune myopathy[J]. N Engl J Med,2016,374(7):664-669.
[6].Perez de Isla L,Alonso R,Watts GF,et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia:5-year safeheart registry follow-up[J]. J Am Coll Cardiol,2016,67(11): 1278-1285.
[7].Dixon DL,Trankle C,Buckley L,et al. A review of PCSK9 inhibition and its effects beyond LDL receptors[J]. J Clin Lipidol,2016,10(5):1073-1080.
[8].Seidah NG,Benjannet S,Wickham L,et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1(NARC-1):liver regeneration and neuronal differentiation[J]. Proc Natl Acad Sci U S A,2003,100(3):928-933.
[9].Artenstein AW,Opal SM. Proprotein convertases in health and disease[J]. N Engl J Med,2011,365(26):2507-2518.
[10].Burke AC,Dron JS,Hegele RA,et al. PCSK9:regulation and target for drug development for dyslipidemia[J]. Annu Rev Pharmacol Toxicol,2017,57:223-244.
[11].Horton JD,Goldstein JL,Brown MS. SREBPs:activators of the complete program of cholesterol and fatty acid synthesis in the liver[J]. J Clin Invest,2002,109(9):1125-1131.
[12].Jeong HJ,Lee HS,Kim KS,et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2[J]. J Lipid Res,2008,49(2):399-409.
[13].Horton JD,Cohen JC,Hobbs HH. Molecular biology of PCSK9:its role in LDL metabolism[J]. Trends Biochem Sci,2007,32(2):71-77.
[14].Momtazi-Borojeni AA,Sabouri-Rad S,Gotto AM,et al. PCSK9 and inflammation:a review of experimental and clinical evidence[J]. Eur Heart J Cardiovasc Pharmacother,2019,5(4):237-245.
[15].Bonaca MP,Nault P,Giugliano RP,et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease:insights from the fourier trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)[J]. Circulation,2017,137(4): 338-350.
[16].Sarwar N,Danesh J,Eiriksdottir G,et al. Triglycerides and the risk of coronary heart disease:10,158 incident cases among 262,525 participants in 29 Western prospective studies[J]. Circulation,2007,115(4):450-458.
[17].Baragetti A,Grejtakova D,Casula M,et al. Proprotein convertase subtilisin-kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism:facts and gaps[J]. Pharmacol Res,2018,130:1-11.
[18].O’Donoghue ML,Fazio S,Giugliano RP,et al. Lipoprotein(a),PCSK9 inhibition,and cardiovascular risk[J]. Circulation,2019,139(12):1483-1492.
[19].Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med,2018,379(22):2097-2107.
[20].Robinson JG,Farnier M,Krempf M,et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1489-1499.
[21].Sabatine MS,Giugliano RP,Wiviott SD,et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events[J]. N Engl J Med,2015,372(16):1500-1509.
[22].Ferri N,Corsini A,Macchi C,et al. Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism:experimental animal models and clinical evidence[J]. Transl Res,2016,173:19-29.
[23].Shapiro MD,Tavori H,Fazio S. PCSK9:from basic science discoveries to clinical trials[J]. Circ Res,2018,122(10):1420-1438.
[24].Langslet G,Emery M,Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia[J]. Expert Rev Cardiovasc Ther,2015,13(5):477-488.
[25].Farnier M. An evaluation of alirocumab for the treatment of hypercholesterolemia[J]. Expert Rev Cardiovasc Ther,2015,13(12):1307-1323.
[26].Gibbs JP,Slatter JG,Egbuna O,et al. Evaluation of evolocumab (AMG 145),a fully human anti-PCSK9 IgG2 monoclonal antibody, in subjects with hepatic impairment[J]. J Clin Pharmacol,2017,57(4):513-523.
[27].Giugliano RP,Mach F,Zavitz K,et al. Cognitive function in a randomized trial of evolocumab[J]. N Engl J Med,2017,377(7):633-643.
[28].Ridker PM,Revkin J,Amarenco P,et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients[J]. N Engl J Med,2017,376(16):1527-1539.
[29].Fitzgerald K,White S,Borodovsky A,et al. A highly durable RNAi therapeutic inhibitor of PCSK9[J]. N Engl J Med,2017,376(1):41-51.
[30].Rosenson RS,Hegele RA,Fazio S,et al. The evolving future of PCSK9 inhibitors[J]. J Am Coll Cardiol,2018,72(3):314-329.
[31].Ray KK,Landmesser U,Leiter LA,et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol[J]. N Engl J Med,2017,376(15):1430-1440.
[32].Landlinger C,Pouwer MG,Juno C,et al. The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol,vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice[J]. Eur Heart J,2017,38(32):2499-2507.
[33].Zhang Y, Ultsch M, Skelton NJ, et al. Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonists[J]. Nat Struct Mol Biol,2017,24(10):848-856.
[34].Wang X,Raghavan A,Chen T,et al. CRISPR-Cas9 targeting of PCSK9 in human hepatocytes in vivo-brief report[J]. Arterioscler Thromb Vasc Biol,2016,36(5):783-786.
[35].Chadwick AC,Wang X,Musunuru K. In vivo base editing of PCSK9 (proprotein convertase subtilisin/kexin type 9) as a therapeutic alternative to genome editing[J]. Arterioscler Thromb Vasc Biol,2017,37(9):1741-1747.
[36].Farnier M,Hovingh GK,Langslet G,et al. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia:an open-label extension of the ODYSSEY program[J]. Atherosclerosis,2018,278:307-314.
[37].Roth EM,Goldberg AC,Catapano AL,et al. Antidrug antibodies in patients treated with alirocumab[J]. N Engl J Med,2017,376(16):1589-1590.
[38].Du H,Li X,Su N,et al. Proprotein convertase subtilisin/kexin 9 inhibitors in reducing cardiovascular outcomes:a systematic review and meta-analysis[J]. Heart,2019,105(15):1149-1159.
[39].乐健,何胜虎.前蛋白转化酶枯草溶菌素9致动脉粥样硬化的机制研究进展[J].心血管病学进展,2019,40(7):1000-1003.
[40].Brown M,Ahmed S. Emerging role of proprotein convertase subtilisin/kexin type-9(PCSK-9) in inflammation and diseases[J]. Toxicol Appl Pharmacol,2019,370:170-177.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(7):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(7):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[3]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(7):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[4]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(7):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[5]王申仪 阳军.基于RNA疗法在动脉粥样硬化性心血管疾病血脂管理的研究进展[J].心血管病学进展,2021,(4):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
Wang Shenyi,Yang Jun.Era of RNA-based Therapies in Lipid Management of?oronary Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(7):369.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.019]
[6]刘力黎 陈诚 张丽敏.血脂水平与心房颤动相关性研究进展[J].心血管病学进展,2021,(6):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
LIU Lili,CHEN Cheng,ZHANG Limin.Serum Lipid Level and Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2021,(7):539.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.015]
[7]许海南 龙明智.新型降脂药物干扰小RNA Inclisiran最新研究进展[J].心血管病学进展,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
XU Hainan,LONG Mingzhi.Small Interfering RNA Inclisiran[J].Advances in Cardiovascular Diseases,2021,(7):590.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.004]
[8]袁荣辉 白春林.贝派地酸降脂疗效及安全性的研究进展[J].心血管病学进展,2021,(9):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
(.Shanxi Medical University,Taiyuan 0000,Shanxi,et al.YUAN Ronghui1,BAI Chunlin2[J].Advances in Cardiovascular Diseases,2021,(7):809.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[9]刘杨 陈明.冠心病的治疗新方向——PCSK9抑制剂[J].心血管病学进展,2021,(9):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
New Direction of Coronary Heart Disease TreatmentPCSK9 Inhibitors.E-mailchenmingcq77@163.com[J].Advances in Cardiovascular Diseases,2021,(7):820.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
[10]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(7):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[11]黄橙 李波 李志勇 陈紫君.过低LDL-C在动脉粥样硬化性心血管疾病中潜在风险循证学证据[J].心血管病学进展,2023,(11):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]
Huang Cheng,Li Bo,Li Zhiyong,et al.The Evidence of the Potential Risk of Excessively Low Levels of LDL-C in ASCVD[J].Advances in Cardiovascular Diseases,2023,(7):1041.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.019]